Primary Biliary Cholangitis
69
16
22
25
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
15 trials with published results (22%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
11.6%
8 terminated out of 69 trials
75.8%
-10.8% vs benchmark
29%
20 trials in Phase 3/4
60%
15 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 25 completed trials
Clinical Trials (69)
LEOPARD Prospective Validation Cohort 1
LEOPARD Training and Validation Data Collection Study
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
Patients With Primary Biliary Cholangitis(PBC)
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
Austrian PBC Registry
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
Evidence Based Mental Wellness Programming Online for Adults Across Chronic Physical Conditions
Patients With Primary Biliary Cholangitis